Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

Secukinumab at a subcutaneous dose of 150 mg, with either sub cutaneous or intravenous loading, provided significant reductions in the signs and symptoms of ankylosing spondylitis at week 16, and was sustained through 52 weeks.